KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulgent Genetics (FLGT) Payables (2016 - 2025)

Fulgent Genetics' Payables history spans 10 years, with the latest figure at $19.1 million for Q4 2025.

  • For Q4 2025, Payables rose 1.89% year-over-year to $19.1 million; the TTM value through Dec 2025 reached $19.1 million, up 1.89%, while the annual FY2025 figure was $19.1 million, 1.89% up from the prior year.
  • Payables for Q4 2025 was $19.1 million at Fulgent Genetics, up from $18.6 million in the prior quarter.
  • Across five years, Payables topped out at $42.9 million in Q2 2022 and bottomed at $14.7 million in Q2 2021.
  • The 5-year median for Payables is $20.0 million (2022), against an average of $22.4 million.
  • The largest annual shift saw Payables skyrocketed 510.86% in 2021 before it plummeted 42.42% in 2023.
  • A 5-year view of Payables shows it stood at $20.5 million in 2021, then surged by 40.2% to $28.7 million in 2022, then tumbled by 42.42% to $16.5 million in 2023, then grew by 13.5% to $18.8 million in 2024, then grew by 1.89% to $19.1 million in 2025.
  • Per Business Quant, the three most recent readings for FLGT's Payables are $19.1 million (Q4 2025), $18.6 million (Q3 2025), and $19.4 million (Q2 2025).